Moyo, EnosBarham, LeelaMhango, Malizgani2022-10-032022-10-032022Moyo, E. et al. (2022). Estimating the budget impact of adopting tenofovir/emtricitabine for pre-exposure prophylaxis of HIV in the public health sector in Namibia (2021 – 2023). Journal of Infection and Public Health, 15(10), 1147-1155. https://doi.org/10.1016/j.jiph.2022.09.0031876-0341https://doi.org/10.1016/j.jiph.2022.09.003http://hdl.handle.net/10566/8000Namibia started implementing pre-exposure prophylaxis (PrEP) of Human Immunodeficiency Virus (HIV) in 2016, no study to determine its budget impact has been conducted. This study, therefore, aimed to estimate the budget impact of adopting tenofovir/emtricitabine for PrEP of HIV for all eligible people in the public health sector in Namibia from 2021 to 2023. Methods: A country-specific model was developed for this budget impact analysis (BIA). PrEP has targeted all eligible people in Namibia who receive health services from the public sector. It was assumed that the adherence rate was 75% and PrEP effectiveness 60% in this study. Costs used in this study were taken from a study that included Namibian costs.enHIVPublic healthPrEPNamibiaPublic sectorArticle